Testicular Microlithiasis
Incidental Intratesticular Calcifications and the Cancer-Risk Debate
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (imaging finding)
Reference only. Not medical advice.
What can go wrong
The principal risk of TM is iatrogenic anxiety and over-investigation. Genuine cancer risk is concentrated in men with concurrent risk factors, in whom TM should prompt heightened vigilance and, in select cases, surveillance. A new solid lesion on any scan - with or without TM - always requires urologic evaluation.
This is something to take to a clinician. The Atlas can tell you what is known about testicular microlithiasis in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testicular microlithiasis (TM) is the ultrasound finding of multiple tiny calcifications within the seminiferous tubules, classically a 'starry sky' appearance. Prevalence is roughly 0.7-6% in general/symptomatic populations and much higher in high-risk groups (cryptorchidism, infertility, disorders of sex development). Its relationship to testicular cancer is the enduring controversy: TM is strongly associated with germ cell tumors in referred and high-risk populations, but in isolation - without other risk factors - the cancer risk is close to that of the general population. Modern guidance has moved away from routine surveillance ultrasound for low-risk men toward risk-stratified, individualized management.
The incidentaloma that launched a thousand unnecessary scans.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The microliths are calcified concretions of degenerated cellular debris within seminiferous tubules, reflecting a disturbance of tubular clearance. TM is a marker of testicular dysgenesis - the same developmental milieu that underlies germ cell neoplasia in situ, cryptorchidism, and impaired spermatogenesis - which is why it clusters with both infertility and cancer risk factors rather than causing cancer directly.
The catch: a marker of risk factors, not an independent cause
The controversy is a lesson in selection bias. In populations referred for scrotal ultrasound - already enriched for pathology - TM travels with tumors, generating alarming relative risks (~20-fold). But in an unselected man with isolated TM and no other risk factors, that association largely evaporates. The clinical harm of over-surveillance (anxiety, unnecessary scans, cascade biopsies) is real, which is why guidelines now reserve surveillance for men who also have risk factors (cryptorchidism, prior GCT, atrophy, infertility, a clustered/bilateral pattern) and otherwise emphasize self-examination.
When this is an emergency
Incidental scrotal ultrasound finding of five or more microliths per field ('classic' TM). Management hinges on associated features: age, cryptorchidism, prior/contralateral GCT, atrophy, infertility, and a clustered/bilateral versus limited/unilateral pattern all raise concern.
What it does to fertility
TM itself is not established as a cause of infertility, but it co-occurs with subfertility because both share a dysgenic testicular substrate; TM is frequently found during infertility ultrasounds. Its main relevance to reproductive-age men is the (usually low) cancer-risk conversation and, in high-risk men, heightened vigilance - rather than a direct effect on sperm.
What people get wrong
Often saidMicrolithiasis means you'll get testicular cancer
ActuallyIn an otherwise low-risk man with isolated TM, the cancer risk is close to that of the general population; the alarming figures come from already high-risk, referred populations.
Often saidEveryone with TM needs regular ultrasounds
ActuallyCurrent guidance recommends against routine surveillance ultrasound for low-risk TM, favoring self-examination and reserving surveillance for men with additional risk factors.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
The people taking it
Often found incidentally in men undergoing scrotal ultrasound for pain, infertility, or a lump; over-represented among men with cryptorchidism, infertility, or disorders of sex development.
What we do not know
- Which combinations of risk factors justify active surveillance versus reassurance?
- Does TM mark a clinically meaningful, independent fertility deficit or merely accompany one?
At a glance
- General-population prevalence
- ~0.7-6% (varies by population/method)
- Referred-population data
- One 4,819-patient series: TM prevalence ~0.68%, RR of concurrent tumor ~21.6
- Isolated TM, no risk factors
- Cancer risk near general population
- High-risk groups
- Cryptorchidism, infertility, DSD, prior GCT, atrophy
- Modern guidance
- No routine surveillance ultrasound for low-risk TM; individualized approach
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testicular Microlithiasis. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Referred-population TM prevalence/tumor-risk study2000
TM prevalence ~0.68%; ~21.6-fold relative risk of concurrent tumor in referred men
Systematic review and clinical guidelines on TM2019
Supports risk-stratified, individualized management over blanket surveillance
Contemporary framework for risk-stratified TM management2023-2026
Moves from incidentaloma to actionable, factor-based stratification